

CONCERT PHARMACEUTICALS, INC.

FORM 8-K (Current report filing)

Filed 09/08/17 for the Period Ending 09/08/17

Address	99 HAYDEN AVENUE SUITE 500 LEXINGTON, MA, 02421
Telephone	781-860-0045
CIK	0001367920
Symbol	CNCE
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): September 7, 2017

Concert Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

**Delaware
(State or Other Jurisdiction
of Incorporation)**

**001-36310
(Commission
File Number)**

**20-4839882
(IRS Employer
Identification No.)**

**99 Hayden Avenue, Suite 500
Lexington, Massachusetts
(Address of Principal Executive Offices)**

**02421
(Zip Code)**

Registrant's telephone number, including area code: (781) 860-0045

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 1.02. Termination of a Material Definitive Agreement.

On September 7, 2017, Concert Pharmaceuticals, Inc. ("the Company") paid a total of \$30.8 million to Hercules Capital, Inc ("Hercules"), representing the principal, accrued and unpaid interest, fees, costs and expenses outstanding under its Loan and Security Agreement (the "Loan Agreement") with Hercules dated June 8, 2017 in repayment of the Company's outstanding obligations under the Loan Agreement. This payoff amount includes a final end of term charge to Hercules in the amount of \$0.7 million, reduced from the \$1.5 million end of term charge required had the debt been held to maturity.

Upon the payment of the \$30.8 million pursuant to a payoff letter between the Company and Hercules, all outstanding indebtedness and obligations of the Company owed to Hercules under the Loan Agreement were paid in full, and the Loan Agreement has been terminated.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CONCERT PHARMACEUTICALS, INC.

Date: September 8, 2017

By: /s/ Roger D. Tung

Roger D. Tung

President and Chief Executive Officer